CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

0.2075 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CASI Pharmaceuticals, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 14, 2024

CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 ↗

March 28, 2024

CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Recap: CASI Pharmaceuticals Q4 Earnings ↗

March 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 07, 2024

Via Benzinga

CASI Pharmaceuticals: Q1 Earnings Insights ↗

May 17, 2023

Via Benzinga

CASI Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

May 01, 2023

Via Benzinga

CASI Pharmaceuticals's Return On Capital Employed Insights ↗

December 26, 2022

Via Benzinga

Recap: CASI Pharmaceuticals Q2 Earnings ↗

August 12, 2022

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients ↗

March 05, 2024

CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 05, 2024

Via Benzinga

Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders ↗

February 17, 2024

LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 25, 2024

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To Know ↗

November 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 03, 2023

Via Benzinga

Why VOXX International Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

October 11, 2023

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

October 11, 2023

Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 27, 2023

Via Benzinga

Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations ↗

August 05, 2023

Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize...

Via Talk Markets

Week In Review: Novartis In $1 Billion Deal For DTx Pharma ↗

July 22, 2023

Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching...

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 10, 2023

Via Benzinga

Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate ↗

September 24, 2022

Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma...

Via Talk Markets

Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday ↗

September 26, 2022

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 23, 2022

Gainers

Via Benzinga

Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs ↗

September 10, 2022

Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment.

Via Talk Markets

$2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying ↗

September 09, 2022

The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

CASI Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

September 09, 2022

According to data from Benzinga Pro, during Q2, CASI Pharmaceuticals's (NASDAQ:CASI) reported sales totaled $8.57 million. Despite a 10.8% increase in earnings, the company posted a loss of $7.49...

Via Benzinga

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying ↗

August 29, 2022

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday ↗

August 17, 2022

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 16, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.